CDTI Innovación invests in Nanoligent alongside Inveready

by CDTI Innovación

Nanoligent is a biotechnology company developing targeted cancer therapies using proteins organized in nanoparticles and conjugated with cytotoxic drugs

Read more

Nanoligent closes €12 million funding round led by Inveready to advance the development of its oncology nanodrug

by Inveready Asset Management

The round was led by Inveready, through its Inveready Biotech IV fund, with additional participation from CDTI, Clave Capital, through its Clave Innohealth fund, and current investors i&i Biotech Fund...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Xcalibur Smart Mapping strengthens its g...

by MCH Private Equity

​Xcalibur Smart Mapping, recognised as the global leader in airborne...

Photos Stream